Inozyme
Inozyme is a biotechnology company based in Boston, Massachusetts, specializing in developing enzyme therapies for rare diseases associated with mineralization disorders, such as ENPP1 and ABCC6 Deficiencies.
Inozyme Overview
Inozyme is a biotechnology company headquartered in Boston, Massachusetts. It specializes in developing therapies for rare diseases characterized by pathologic mineralization and intimal proliferation. The company's key product is INZ-701, a first-in-class enzyme therapy targeting diseases involving low levels of inorganic pyrophosphate (PPi) and adenosine.
Therapies for Rare Diseases
Inozyme focuses on creating treatments for rare diseases driven by abnormal mineralization processes. The primary therapy INZ-701 aims to address conditions caused by insufficient levels of PPi and adenosine. This investigational treatment is delivered subcutaneously and designed for prolonged exposure, enabling infrequent dosing that may improve patient compliance.
Inozyme Clinical Trials
Inozyme is actively engaged in several clinical trials to evaluate the efficacy and safety of INZ-701. The pipeline includes trials for ENPP1 Deficiency and ABCC6 Deficiency. Specific ENPP1 Deficiency trials are organized by patient demographics, including pediatric, infant, and adult trials, along with an observational study. An additional trial is conducted for ABCC6 Deficiency patients.
Genetic Testing and Expanded Access Programs at Inozyme
Inozyme provides genetic testing programs to identify eligible patients suffering from conditions their therapies aim to treat. Additionally, the company offers expanded access programs, providing patients who meet specific criteria with potential access to investigational therapies outside of clinical trials.
Employee Benefits at Inozyme
Inozyme offers a comprehensive and competitive benefits package for its employees. These benefits are designed to support the overall well-being and professional growth of their workforce, reflecting the company’s commitment to attracting and retaining top talent in the biotechnology sector.